ResearcherTUM KlinikumActive in the last 2 years
Lei Ren
Matched on ORCID iD 0000-0001-6477-2630; OpenAlex author ID A5052909666. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 37
2020: 2 papers · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: none · 2025: 1 paper · 2026: 1 paper
Papers 7
- Prognostic implications of superior mesenteric vein/portal vein resection and histologic venous invasion in BR/LA PDAC after neoadjuvant therapy. First author DOI 10.1007/s00423-026-04145-9↗
- Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses. Co-author DOI 10.1016/j.ccell.2025.09.003↗
- Arterial Resection for Pancreatic Cancer: Feasibility and Current Standing in a High-Volume Center. Co-author DOI 10.1097/as9.0000000000000302↗
- Phenotype screens of murine pancreatic cancer identify a Tgf-α-Ccl2-paxillin axis driving human-like neural invasion. Co-author DOI 10.1172/jci166333↗
- Patterns and Relevance of Langerhans Islet Invasion in Pancreatic Cancer. Co-author DOI 10.3390/cancers13020249↗
- Neoadjuvant therapy in pancreatic cancer: what is the true oncological benefit? Co-author DOI 10.1007/s00423-020-01946-4↗
- Indirect cholinergic activation slows down pancreatic cancer growth and tumor-associated inflammation. Co-author DOI 10.1186/s13046-020-01796-4↗
Closest collaborators
The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- İhsan Ekin Demir · 7 shared papers, 2020–2026 · strength 1.15
- Paper Prognostic implications of superior mesenteric vein/portal vein resection and histologic venous invasion in BR/LA PDAC … DOI 10.1007/s00423-026-04145-9↗
- Paper Arterial Resection for Pancreatic Cancer: Feasibility and Current Standing in a High-Volume Center. DOI 10.1097/as9.0000000000000302↗
- Paper Neoadjuvant therapy in pancreatic cancer: what is the true oncological benefit? DOI 10.1007/s00423-020-01946-4↗
- Guralp Onur Ceyhan · 5 shared papers, 2020–2025 · strength 0.65
- Paper Arterial Resection for Pancreatic Cancer: Feasibility and Current Standing in a High-Volume Center. DOI 10.1097/as9.0000000000000302↗
- Paper Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses. DOI 10.1016/j.ccell.2025.09.003↗
- Paper Patterns and Relevance of Langerhans Islet Invasion in Pancreatic Cancer. DOI 10.3390/cancers13020249↗
- Helmut Frieß · 5 shared papers, 2020–2025 · strength 0.65
- Paper Neoadjuvant therapy in pancreatic cancer: what is the true oncological benefit? DOI 10.1007/s00423-020-01946-4↗
- Paper Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses. DOI 10.1016/j.ccell.2025.09.003↗
- Paper Patterns and Relevance of Langerhans Islet Invasion in Pancreatic Cancer. DOI 10.3390/cancers13020249↗
- Helmut Friess · 2 shared papers, 2023–2026 · strength 0.50
- Okan Safak · 3 shared papers, 2021–2025 · strength 0.45
- Paper Arterial Resection for Pancreatic Cancer: Feasibility and Current Standing in a High-Volume Center. DOI 10.1097/as9.0000000000000302↗
- Paper Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses. DOI 10.1016/j.ccell.2025.09.003↗
- Paper Patterns and Relevance of Langerhans Islet Invasion in Pancreatic Cancer. DOI 10.3390/cancers13020249↗
- Carmen Mota Reyes · 3 shared papers, 2020–2025 · strength 0.44
- Paper Neoadjuvant therapy in pancreatic cancer: what is the true oncological benefit? DOI 10.1007/s00423-020-01946-4↗
- Paper Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses. DOI 10.1016/j.ccell.2025.09.003↗
- Paper Phenotype screens of murine pancreatic cancer identify a Tgf-α-Ccl2-paxillin axis driving human-like neural invasion. DOI 10.1172/jci166333↗
- J M. Zhang · 1 shared paper, 2026 · strength 0.33
- Florian Scheufele · 1 shared paper, 2026 · strength 0.33
- Rüdiger Göß · 2 shared papers, 2021–2023 · strength 0.29
- Maximilian Kießler · 2 shared papers, 2023 · strength 0.28
- Linhan Ye · 2 shared papers, 2023–2025 · strength 0.28
- Alexander Muckenhuber · 2 shared papers, 2023–2025 · strength 0.28
- Achim Krüger · 2 shared papers, 2023–2025 · strength 0.28
- Kıvanç Görgülü · 2 shared papers, 2023–2025 · strength 0.28
- Kaan Çifcibaşı · 2 shared papers, 2023–2025 · strength 0.28
- Saliha Elif Yıldızhan · 2 shared papers, 2023–2025 · strength 0.28
- Roland Michael Schmid · 2 shared papers, 2023–2025 · strength 0.28
- Roland Rad · 2 shared papers, 2023–2025 · strength 0.28
- Hana Algül · 2 shared papers, 2023–2025 · strength 0.28
- Dieter Saur · 2 shared papers, 2023–2025 · strength 0.28
- Marc Eric Martignoni · 1 shared paper, 2023 · strength 0.17
- Ilaria Pergolini · 1 shared paper, 2023 · strength 0.17
- Stephan Schorn · 1 shared paper, 2023 · strength 0.17
- Alexander Novotny · 1 shared paper, 2023 · strength 0.17
- Didem Karakaş · 1 shared paper, 2025 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.